$Vivos Therapeutics(VVOS.US)Strange, why is it so weak? It's already clinically approved and planning to be profitable.

Vivos Therapeutics recently received FDA 510(k) clearance for its DNA oral medical device, specifically designed to treat moderate to severe pediatric obstructive sleep apnea (OSA) and snoring. This is the first oral device approved for such pediatric conditions, offering a non-invasive, cost-effective alternative to traditional surgical treatments like adenoidectomy and tonsillectomy, with better long-term efficacy.

Vivos Therapeutics has obtained FDA 510(k) clearance to clinically apply its DNA oral device for treating moderate to severe pediatric obstructive sleep apnea (OSA) and snoring. This approval grants the device market legality, and Vivos plans to rapidly commercialize the technology through collaborations with medical and dental professionals. The company expects rapid revenue expansion, as the device is non-invasive, low-cost, and has demonstrated significant efficacy in clinical trials.

However, despite Vivos' technology being approved and planning profitability, market response and actual revenue growth still require time to observe, depending on the company's ability to successfully implement its marketing strategy and secure sufficient medical partnerships.

The device expands the pharyngeal airway, reducing OSA symptoms and promoting nasal breathing. Clinical trials show a 62.7% improvement in OSA symptoms and a 58% reduction in snoring. Vivos plans to integrate the device into broader pediatric care strategies through collaborations with medical and dental professionals, capturing more market share in the sleep apnea field.